CIK 0001501989
- Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 273521219
- Phone
- +1 650-515-3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-17 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −31,492 | $6.42 | $202K | 300,760 |
| 2026-02-02 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +60,000 | 332,252 | ||
| 2026-02-02 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2025-09-26 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +36,300 | 36,300 | ||
| 2025-09-26 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Performance Stock Units (PSUs) | +18,150 | 18,150 | ||
| 2025-06-16 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −13,884 | $2.69 | $37K | 272,252 |
| 2025-06-13 | BELVIN MARCIA SVP, Chief Scientific Officer | Exercise or conversion | +37,500 | 286,136 | ||
| 2025-06-13 | BELVIN MARCIA SVP, Chief Scientific Officer | Exercise or conversion · Performance Stock Units | −37,500 | 0 | ||
| 2025-03-18 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −19,512 | $0.60 | $12K | 248,636 |
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +35,000 | 210,648 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +57,500 | 268,148 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +30,000 | 205,648 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +57,500 | 263,148 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2025-02-04 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +115,000 | 115,000 | ||
| 2024-08-20 | BELVIN MARCIA SVP, Chief Scientific Officer | Exercise or conversion | +11,250 | 179,829 | ||
| 2024-08-20 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −4,181 | $1.23 | $5K | 175,648 |
| 2024-08-20 | BELVIN MARCIA SVP, Chief Scientific Officer | Exercise or conversion · Performance Stock Units (PSUs) | −11,250 | 0 |
Page 1 of 2 · 30 trades